<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15446">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02905799</url>
  </required_header>
  <id_info>
    <org_study_id>P150938</org_study_id>
    <secondary_id>2016-A01310-51</secondary_id>
    <nct_id>NCT02905799</nct_id>
  </id_info>
  <brief_title>Resveratrol in Knee Osteoarthritis</brief_title>
  <acronym>ARTHROL</acronym>
  <official_title>Evolution of Pain at Three Months by Oral Resveratrol in Primary Knee Osteoarthritis: a Multicenter, Double-blind, Randomized, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Unité de Recherche Clinique (URC) Paris Descartes Cochin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether resveratrol is effective in the treatment
      of painful knee osteoarthritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Osteoarthritis (OA) is the first cause of handicap in individuals over 40 years-old in
      France. OA physiopathology is driven by local joint inflammation responsible for pain and
      joint destruction. Experimental studies have shown that resveratrol, a molecule antagonist
      to the aryl hydrocarbon receptor, has anti-inflammatory and chondroprotective properties in
      vitro and in vivo. The investigators hypothesize that resveratrol, in a new formulation
      developed by the coordinating investigator improving its bioavailability, will decrease pain
      in patients presenting with primary knee OA.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2017</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Participant, Care Provider, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean knee pain in the past 48 hours</measure>
    <time_frame>at 3 months</time_frame>
    <description>Using a numeric rating scale, with 0 = no pain and 100 = maximal pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mean knee pain in the past 48 hours</measure>
    <time_frame>at 6 months</time_frame>
    <description>Using a numeric rating scale, with 0 = no pain and 100 = maximal pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability</measure>
    <time_frame>at 3 months</time_frame>
    <description>Using WOMAC function subscore</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability</measure>
    <time_frame>at 6 months</time_frame>
    <description>Using WOMAC function subscore</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's global assessment of improvement</measure>
    <time_frame>at 3 months</time_frame>
    <description>Using a numeric rating scale, with 0 = no improvement and 100 = maximal improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's global assessment of improvement</measure>
    <time_frame>at 6 months</time_frame>
    <description>Using a numeric rating scale, with 0 = no improvement and 100 = maximal improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of OARSI-OMERACT responders</measure>
    <time_frame>at 3 months</time_frame>
    <description>OARSI-OMERACT response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of OARSI-OMERACT responders</measure>
    <time_frame>at 6 months</time_frame>
    <description>OARSI-OMERACT response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesics and non-steroidal anti-inflammatory drugs (NSAIDs) consumption and intra-articular corticoid or hyaluronic acid injections since last contact</measure>
    <time_frame>at 3 months</time_frame>
    <description>using self-reporting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesics and non-steroidal anti-inflammatory drugs (NSAIDs) consumption and intra-articular corticoid or hyaluronic acid injections since last contact</measure>
    <time_frame>at 6 months</time_frame>
    <description>using self-reporting</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Oral resveratrol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Resveratrol will be administered orally, at the dose of 40 mg twice a day, for one week, then at the dose of 20 mg twice a day, for a total duration of 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered orally twice a day for a total duration of 6 months. Placebo will present with similar conditioning and taste</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral resveratrol</intervention_name>
    <arm_group_label>Oral resveratrol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral placebo</intervention_name>
    <arm_group_label>Oral Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 40 years-old

          -  Knee osteoarthritis fulfilling 1986 ACR criteria

          -  Pain on numeric rating scale ≥ 40/100

          -  Symptom duration ≥ 1 month

          -  4 &gt; Kellgren and Lawrence X-Ray score ≥ 2

          -  No changes in the treatment in the past month

          -  Written consent obtained

          -  Health insurance cover

        Exclusion Criteria:

          -  History of symptomatic crystal or inﬂammatory arthritis

          -  Knee surgery ≤ 1 year

          -  Knee trauma ≤ 2 months

          -  Knee intra-articular injections ≤ 2 months

          -  Neurologic disorder involving the lower limb

          -  Inability to speak or write French

          -  Participation to another biomedical research

          -  Contraindication to resveratrol or hypersensitivity to any of its constituents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christelle NGUYEN, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Université Paris Descartes, PRES Sorbonne Paris Cité</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>François Rannou, MD, PhD</last_name>
    <phone>+33 1 58 41 25 35</phone>
    <email>francois.rannou@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandra BRUNEAU, Master</last_name>
    <phone>+ 33 1 58 41 12 13</phone>
    <email>alexandra.bruneau@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rehabilitation department , CHU Clermont-Ferrand</name>
      <address>
        <city>Cebazat</city>
        <zip>63118</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuel Coudeyre, MD, PhD</last_name>
      <phone>+33473750900</phone>
      <email>ecoudeyre@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rheumatology Department, Saint Antoine Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francis Berenbaum, MD, PhD</last_name>
      <phone>+33149282520</phone>
      <email>francis.berenbaum@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rehabilitation Department, Cochin Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>François Rannou, MD, PhD</last_name>
      <phone>+33 1 58 41 25 35</phone>
      <email>francois.rannou@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 21, 2017</lastchanged_date>
  <firstreceived_date>September 14, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Knee</keyword>
  <keyword>Resveratrol</keyword>
  <keyword>Oral Treatment</keyword>
  <keyword>Pain</keyword>
  <keyword>Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
